

Prevalence of carbapenems resistant bacteria: Case of three health facilities in Lomé, Togo

ABSTRACT

Aims: The purpose of this study was to determine the prevalence of bacteria resistant to carbapenems within three reference health facilities in Lomé, Togo.

Methods: It was a descriptive and analytical study carried out between April and August 2016 within three medical bacteriology laboratories: Institut National d'Hygiène (INH), Sylvanus Olympio and Campus Teaching Hospitals. Samples of various origins were processed according to national standard procedures. Identification of bacteria was carried out according to the Biomérieux API® technique, antibiotics susceptibility test done according to the 2015 recommendations of the Comité de l'antibiogramme de la Société Française de Microbiologie (CA-SFM). Thus, enterobacteria with a decreased susceptibility to ertapenem and *Pseudomonas aeruginosa*, *Acinetobacter baumannii* resistant to imipenem were included.

Results: During the study, 306 strains were isolated at Sylvanus Olympio Teaching Hospital, 77 at Campus Teaching Hospital, and 520 at INH. The prevalence was 7.19% (n=22) for Sylvanus Olympio, 2.59% (n=2) for Campus, and 0.77% (n=4) for INH. Among these 28 strains from different origins, 57.14% (n=16) were isolated from hospitalized patients. Most of the strains, 64.29% (n=18) were isolated from urines, 32.14% from pus (n=9), and 3.57% from CSF (n=1). It was 14 strains of *Acinetobacter baumannii*, 11 strains of *Enterobacter cloacae*, 1 strain of *Pseudomonas aeruginosa*, 1 strain of *Klebsiella pneumoniae*, and 1 strain of *Escherichia coli*. Two strains of *E. cloacae* and the strain of *P. aeruginosa* were resistant to colistin.

Conclusion: Cases of strains with decreased susceptibility to carbapenems are isolated within hospitals in Lomé, so a molecular characterization as well as an epidemiological surveillance is needed.

Keywords: *Acinetobacter baumannii*; carbapenems resistance; Enterobacteria; *Pseudomonas aeruginosa*; Lomé

1. INTRODUCTION

Gram-negative bacteria are the major isolated in human pathology. Over the years, their susceptibility to the different antibiotics became very limited, decreasing the therapeutic options. Indeed, we noticed the development of resistance especially to the main class of antibiotics used for their treatment: the beta-lactams.

The detection of the first extended spectrum beta-lactamase SHV-2 encoded by a strain of *K. pneumoniae* isolated in Germany in 1985 [1] announced the era of these enzymes which represent nowadays a real public health issue. β -lactamases are enzymes which inactivate the molecules belonging to the class of β -lactams. They are numerous and from different types depending on their targeted antibiotic. Some are present naturally within some bacteria such as the *Acinetobacter*'s natural cephalosporinase [2]. However, the acquisition of the so-called extended spectrum β -lactamases

from the fact that they inactivate all the β -lactams antibiotics with the exception of the carbapenems makes difficult the treatment of some infections. To these enzymes, carbapenemases will appear and target carbapenems, last resort of this family. This resistance was first detected in London in 1982 [3] and since then many reports took place in various regions of the world [4]. Their spread represents a significant threat to public health.

Africa is not spared, in fact singular cases of sporadic outbreaks are noticed in all parts of the continent in humans [5–9], in animals [10] and in the environment [11]. With this in mind, we then wanted to carry out a study on the prevalence of the resistance to carbapenems within the city of Lomé.

2. MATERIAL AND METHODS

It was a prospective study between April and August 2016 within three medical bacteriology laboratories in Lomé: the laboratories of the Sylvanus Olympio and Campus Teaching Hospitals and that of Institut National d'Hygiène (INH). These three facilities belong to the Togolese public sector and are those offering medical bacteriology services. In this study, we have included all the Gram-negative bacilli (GNB) which are resistant to carbapenems after a susceptibility testing.

The treatment of samples is done within different laboratories according to the national standardized procedures in order to isolate the bacteria. The identification of the bacteria was done through the traditional approach (Gram coloration, oxidase and biochemical test) or analytical profil index (API®) by Bioréieux depending on the cases. The susceptibility to antibiotics was done through antibiotics disks diffusion method on agar medium in accordance with the standards of the national standardized procedures. For the study of susceptibility to carbapenems, disks of ertapenem and imipenem at 10 μ g were used. It was about testing as a marker ertapenem for enterobacteria and imipenem for *Pseudomonas* and *Acinetobacter* strains. The third generation cephalosporins tested were: ceftriaxone, cefsulodine, ceftazidime, cefotaxime, cefpodoxime, cefixime, cefotetan, cefepime, ceftiofime, cefotiam depending on their availability. The identification of resistant bacteria was done through the phenotypic method. The interpretations were done according to the 2015 recommendations of the Comité de l'antibiogramme de la Société Française de Microbiologie (CA-SFM) [12]. *Pseudomonas* and *Acinetobacter* were resistant if Imipenem inhibition diameter was <17 mm and susceptible if the diameter was ≥ 20 mm for *Pseudomonas* and ≥ 22 mm for *Acinetobacter*. Enterobacteria were considered as susceptible if ertapenem inhibition diameter was ≥ 25 mm and resistant if the diameter was < 22 mm.

3. RESULTS

In our study, 306 bacterial strains were isolated at Sylvanus Olympio Teaching Hospital, 77 at Campus Teaching Hospital, and 520 at INH. Strains resistant to third-generation cephalosporins were isolated, it was about 19.28% (n=59); 14.28% (n=11); and 18.07% (n=94) respectively for Sylvanus Olympio Teaching Hospital, Campus Teaching Hospital, and INH (Table 1). The proportion of bacteria resistant to carbapenems was 7.19% (n=22) for Sylvanus Olympio, 2.59% (n=2) for Campus, and 0.77% (n=4) for INH, representing a total of 28 strains. Among these strains, more than half representing 57.14% (n=16) were isolated in hospitalized patients. Most of the strains, 64.29% (n=18) were isolated from urines, 32.14% from pus (n=9), and 3.57% from CSF (n=1).

At Sylvanus Olympio Teaching Hospital and INH, all the strains resistant to imipenem were strains of *A. baumannii*; at Campus, it was one strain of *A. baumannii* and one strain of *P. aeruginosa*. The strains resistant to ertapenem were exclusively represented by *Enterobacter cloacae* at INH (2), and at Sylvanus Olympio Teaching Hospital it was seven (7) strains of *E. cloacae* and one (1) strain of *Escherichia coli*. No information about patients' recent trips or history of hospitalization was mentioned.

Strains producing extended spectrum beta lactamases were isolated during this period. We noticed 19.28% (n=59) at Sylvanus Olympio, 14.28% (n=11) at Campus and 18.07% (n=94) at INH. All strains resistant to carbapenems were susceptible to colistin except two strains of *E. cloacae* isolated at Sylvanus Olympio and one strain of *P. aeruginosa* at Campus. Various resistances associated were noticed in particular to ciprofloxacin and to aminoglycosides (gentamicin, amikacin, tobramycin) Indeed, most of these strains were ciprofloxacin (n=26) and gentamicin (n=25) resistant (Table 2)

Comment [TKC1]: May I know how the calculation of the percentage in your study and the rests? Any significant statistic could be done?

Comment [UMO2R1]: For each percentage of this sentence I use the total number of bacteria isolated in the study period of each center.

Table 1: Distribution of bacteria resistant to carbapenems in the three laboratories

	<i>K.pneumoniae</i>	<i>E. cloacae</i>	<i>E. coli</i>	<i>A.baumannii</i>	<i>P. aeruginosa</i>	Total
CHU Sylvanus Olympio	1	7	1	13	0	22
CHU Campus	0	0	0	1	1	2
INH	0	2	0	2	0	4
Total	1	9	1	16	1	28

Comment [TKC3]: Please show any relevant disc diffusion assay pictures to support the findings. It would be better to show a table to include the disc diffusion results such as diameter (mm) zone inhibition.

Table 2: Proportion of associated resistance to quinolones, aminoglycosides and colistin in each type of bacteria

	Ciprofloxacin	Gentamicin	Tobramycin	Amikacin	Colistin
<i>A. baumannii</i>	15 (93,75%)	16 (100%)	0	8 (50%)	0
<i>P. aeruginosa</i>	1 (100%)	1 (100%)	1 (100%)	1 (100%)	1 (100%)
<i>E. cloacae</i>	8 (88,88%)	6 (75%)	6 (75%)	1 (11,11%)	2 (22,22%)
<i>E.coli</i>	1 (100%)	1 (100%)	1 (100%)	0	0
<i>K.pneumoniae</i>	1 (100%)	1 (100%)	1 (100%)	0	0
Total	26	25	9	10	3

Comment [TKC4]: Any significant findings, since no much significant difference from the results shown by ciprofloxacin and gentamicin?

Comment [UM05R4]: This findings highlight the fact that all these strains were ciprofloxacin and gentamicin resistant.

Comment [TKC6]: Would this ciprofloxacin and other antibiotics also included significantly in the study besides carbapenems or as a comparison?

Comment [UM07R6]: Here it is associated resistance of carbapenem resistant strains. The goal here is to observe multiple resistance of these strains.

4. DISCUSSIONS

It is the first study carried out on strains' susceptibility to carbapenems in Togo. The prevalence of resistance to carbapenems varies according to the level of importance of each facility. Indeed, Sylvanus Olympio Teaching Hospital is the reference center in Togo, followed by Campus Teaching Hospital in terms of hospitalization and follow-up of patients of the public sector; that justifies the fact that the prevalence is more significant. In fact, the strains resistant to carbapenems are often found in hospitalized patients in intensive care units or in people with history of multiple hospitalizations due to strains' selection under the pressure of different antibiotic treatments [13]. More than half of the strains resistant to carbapenems (57.41%) were isolated in hospitalized patients in our study, what confirms this fact. Regarding INH which mission is to do bio-medical analyses, the low prevalence noticed is understandable. Furthermore, the presence of strains resistant to carbapenems within INH could let think of community strains but it should be recalled that INH collects also samples from private clinics of the city, what explains the high number of samples.

Data on the history of patients' hospitalization and trips could not be collected. These information are necessary especially in terms of epidemiology of the antibiotic resistance. This aspect thus needs improvement.

Enterobacteria resistant to carbapenems were dominated by *E. cloacae* (7 at Sylvanus Olympio and 2 at INH); only one strain of *K. pneumoniae* as well as one of *E. coli* were described. Indeed these three bacteria are the most described among those carrying genes encoding a carbapenemase [14]. In Canada, the report of a surveillance of enterobacteria resistant to carbapenems (ERC) in 2014 found the same bacteria with higher rates ; their surveillance was based on 33 hospitals [15]. In the north of our country, in Burkina Faso, it was described a plasmid carrying *bla*_{OXA-181}, a gene encoding a carbapenemase within an *E. coli* [9]. In fact, that country for not having a port, maintains a business relationship in which goods are sent from our port to their country. The plasmid-mediated resistance spreading quickly enough, it is necessary to reinforce the epidemiological surveillance in order to avoid any possible outbreak.

Apart from the ERCs, some non-fermentative bacteria such as *P. aeruginosa* and *A. baumannii* are also incriminated as carrying resistance to carbapenems. These bacteria are generally signs of infections associated with care because these are found in hospital environment [5,16]. Thus it is not surprising that these bacteria are mostly found in the two hospitals in the study. In Africa, strains of *A. baumannii* were described as carrying genes of carbapenemases in clinics in Ethiopia and in Algeria [5,7], and in the environment in Senegal [11]. Strains of *P. aeruginosa* which produce carbapenemase were also described in Nigeria [6]. It is essential to reinforce hygiene practices within our hospitals in order to avoid the spread of these resistant strains.

The bacteria resistant to carbapenems are most often multi-resistant. In our study, most of these strains were resistant to ciprofloxacin and gentamicin so quinolons and aminoglycosides options of threatening these infections are down. To treat infections caused by these strains, colistin will be the antibiotic of last resort. However, in our study, 2 strains of *E. cloacae* and one of *P. aeruginosa* were resistant to colistin. To our knowledge, this antibiotic is not yet used in hospitals in our city. Thus, further investigations should be conducted to establish the acquisition mechanisms of this resistance.

5. CONCLUSION

This work has highlighted resistance of bacteria to carbapenems in the city of Lome through its three reference centers in terms of medical bacteriology. Awareness about proper use of antibiotics associated with epidemiological surveillance are essential in order to avoid spread of the resistance to carbapenems. Furthermore, molecular studies should be done on these bacteria in order to identify the genes they carry.

COMPETING INTERESTS

Authors have declared that no competing interests exist

REFERENCES

1. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. *Antimicrob Agents Chemother*. 1985 Aug;28(2):302–7.
2. Héritier C, Poirel L, Nordmann P. Cephalosporinase over-expression resulting from insertion of ISAb1 in *Acinetobacter baumannii*. *Clin Microbiol Infect*. 2006 Feb 1;12(2):123–30.
3. Yang YJ, Wu PJ, Livermore DM. Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two *Serratia marcescens* isolates. *Antimicrob Agents Chemother*. 1990 May;34(5):755–8.
4. Queenan AM, Bush K. Carbapenemases: the Versatile β -Lactamases. *Clin Microbiol Rev*. 2007 Jul;20(3):440–58.
5. Djahmi N, Donyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne J-P. Epidemiology of Carbapenemase-Producing Enterobacteriaceae and *Acinetobacter baumannii* in Mediterranean Countries. *BioMed Res Int* [Internet]. 2014 ;2014. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052623/>
6. Ogbolu DO, Webber MA. High-level and novel mechanisms of carbapenem resistance in Gram-negative bacteria from tertiary hospitals in Nigeria. *Int J Antimicrob Agents*. 2014 May 1;43(5):412–7.

[Tapez ici]

- 162 7. Pritsch M, Zeynudin A, Messerer M, Baumer S, Liegl G, Schubert S, et al. First report on blaNDM-1-producing
 163 *Acinetobacter baumannii* in three clinical isolates from Ethiopia. BMC Infect Dis [Internet]. 2017 Mar 1 [cited 2017 Mar
 164 12];17. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333390/>
- 165 8. Dortet L, Poirel L, Anguel N, Nordmann P. New Delhi Metallo- β -Lactamase 4-producing *Escherichia coli* in
 166 Cameroon. Emerg Infect Dis. 2012 Sep;18(9):1540–2.
- 167 9. Ouédraogo A-S, Compain F, Sanou M, Aberkane S, Bouzinbi N, Hide M, et al. First Description of IncX3 Plasmids
 168 Carrying blaOXA-181 in *Escherichia coli* Clinical Isolates in Burkina Faso. Antimicrob Agents Chemother. 2016 Jan
 169 5;60(5):3240–2.
- 170 10. Yousfi M, Mairi A, Bakour S, Touati A, Hassissen L, Hadjadj L, et al. First report of NDM-5-producing *Escherichia*
 171 *coli* ST1284 isolated from dog in Bejaia, Algeria. New Microbes New Infect. 2015 Sep 10;8:17–8.
- 172 11. Kempf M, Rolain J-M, Diatta G, Azza S, Samb B, Mediannikov O, et al. Carbapenem Resistance and
 173 *Acinetobacter baumannii* in Senegal: The Paradigm of a Common Phenomenon in Natural Reservoirs. PLoS ONE
 174 [Internet]. 2012 Jun 20 [cited 2017 Aug 7];7(6). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380006/>
- 175 12. Bonnet R., al. Antibiotic Committee of the French Microbiology Society, 2015 Recommendations [Internet].
 176 French Society of Microbiology; 2015. Available from: <http://www.sfm-microbiology.org/>
- 177 13. Abbas M., A. Cherkaoui, C. Fankhauser, S. Harbarth, J. Schrenzel. Carbapenemases: clinical and
 178 epidemiological implications for Switzerland. Rev Med Switzerland. 2012; (338): 882-9.
- 179 14. Nordmann P, Naas T, Poirel L. Global Spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect
 180 Dis. 2011 Oct;17(10):1791–8.
- 181 15. Quebec Public Health Laboratory. Report on Laboratory Surveillance of Isolated Carbapenem Resistant
 182 Enterobacteriaceae Strains in Quebec in 2014- Annual Report [Internet]. National Institute of Public Health; 2015.
 183 Available from: inspq.qc.ca
- 184 16. Nordmann P. Resistance to carbapenems in gram-negative bacilli. medicine / science. 2010 Nov; 26 (11): 950-9.

Comment [TKC8]: Please italicize it.

Comment [TKC9]: Please italicize it.

Comment [TKC10]: Please italicize it.

Comment [TKC11]: Please italicize it.

Comment [TKC12]: Please italicize it.

Comment [TKC13]: Can also include any NCCLS?